Ritu Salani, MD, MBA, UCLA Health in Los Angeles, CA, emphasizes the importance of clinical trials in advancing the management of uterine cancer with immunotherapy. She highlights the significance of trials incorporating immunotherapy combinations and sequential therapies, aiming to improve both the quantity and quality of patients’ lives. Prof. Salani stresses the need for diverse patient populations in these trials to ensure inclusivity and relevance to real-world scenarios. Additionally, she underscores the importance of innovative trial design to optimize patient access and minimize toxicity. This interview took place at the 2024 PRIMO meeting in Honolulu, Hawaii.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
